Literature DB >> 11294829

Dual level inhibition of E2F-1 activity by adeno-associated virus Rep78.

R B Batchu1, M A Shammas, J Y Wang, N C Munshi.   

Abstract

E2F-1, a major cellular transcription factor, plays a pivotal role in regulating the cell cycle. The activity of E2F-1 is negatively regulated by its interaction with retinoblastoma protein (pRB), and disruption of the pRB-E2F-1 complex, a hallmark of cellular transformation by DNA tumor viruses, leads to cell proliferation. Adeno-associated virus-2 (AAV) is known to have onco-suppressive properties against DNA tumor viruses. Here we provide, for the first time, the molecular basis for antioncogenic activity of AAV. Rep78, a major regulatory protein of AAV, interacts at the protein level with E2F-1 and stabilizes the pRB-E2F-1 complex. At the DNA level, Rep78 binds to a putative site on the E2F-1 promoter and down-regulates the adenovirus-induced E2F-1 transcription. This dual level of Rep78 activity leads to decreased cellular levels of free E2F-1, leading to its onco-suppressive properties.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11294829     DOI: 10.1074/jbc.M008154200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  11 in total

1.  Human parvovirus B19 causes cell cycle arrest of human erythroid progenitors via deregulation of the E2F family of transcription factors.

Authors:  Zhihong Wan; Ning Zhi; Susan Wong; Keyvan Keyvanfar; Delong Liu; Nalini Raghavachari; Peter J Munson; Su Su; Daniela Malide; Sachiko Kajigaya; Neal S Young
Journal:  J Clin Invest       Date:  2010-09-20       Impact factor: 14.808

2.  How adeno-associated virus Rep78 protein arrests cells completely in S phase.

Authors:  Carole Berthet; Kenneth Raj; Philippe Saudan; Peter Beard
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-12       Impact factor: 11.205

3.  Identification of an adeno-associated virus Rep protein binding site in the adenovirus E2a promoter.

Authors:  John M Casper; Jennifer M Timpe; John David Dignam; James P Trempe
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

4.  Adeno-associated virus type 2 increases proteosome-dependent degradation of p21WAF1 in a human papillomavirus type 31b-positive cervical carcinoma line.

Authors:  Samina Alam; Ellora Sen; Heidi Brashear; Craig Meyers
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

5.  Adeno-associated virus rep protein-mediated inhibition of transcription of the adenovirus major late promoter in vitro.

Authors:  Patrick G Needham; John M Casper; Vivian Kalman-Maltese; Kristin Verrill; John David Dignam; James P Trempe
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

6.  Adeno-associated virus type 2 induces apoptosis in human papillomavirus-infected cell lines but not in normal keratinocytes.

Authors:  Samina Alam; Craig Meyers
Journal:  J Virol       Date:  2009-07-22       Impact factor: 5.103

7.  Identification of cellular proteins that interact with the adeno-associated virus rep protein.

Authors:  Kevin Nash; Weijun Chen; Max Salganik; Nicholas Muzyczka
Journal:  J Virol       Date:  2008-10-29       Impact factor: 5.103

8.  Adeno-associated virus type 2 infection activates caspase dependent and independent apoptosis in multiple breast cancer lines but not in normal mammary epithelial cells.

Authors:  Samina Alam; Brian S Bowser; Michael J Conway; Mohd Israr; Apurva Tandon; Craig Meyers
Journal:  Mol Cancer       Date:  2011-08-09       Impact factor: 27.401

9.  Reannotation of the CELO genome characterizes a set of previously unassigned open reading frames and points to novel modes of host interaction in avian adenoviruses.

Authors:  Stefan Washietl; Frank Eisenhaber
Journal:  BMC Bioinformatics       Date:  2003-11-07       Impact factor: 3.169

10.  Viral and Cellular Components of AAV2 Replication Compartments.

Authors:  Rebecca Vogel; Michael Seyffert; Bruna de Andrade Pereira; Cornel Fraefel
Journal:  Open Virol J       Date:  2013-10-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.